198 related articles for article (PubMed ID: 7664282)
21. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
22. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
23. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
24. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
25. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
[TBL] [Abstract][Full Text] [Related]
26. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Phillips GL; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1033-42. PubMed ID: 21074630
[TBL] [Abstract][Full Text] [Related]
27. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage.
Willson JK; Fischer PH; Tutsch K; Alberti D; Simon K; Hamilton RD; Bruggink J; Koeller JM; Tormey DC; Earhart RH
Cancer Res; 1988 Oct; 48(19):5585-90. PubMed ID: 3416311
[TBL] [Abstract][Full Text] [Related]
28. Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum.
Kligerman MM; Blumberg AL; Glick JH; Nelson DF; Glover D; Yuhas JM; Amols HI; Goodman RL
Cancer Clin Trials; 1981; 4(4):469-74. PubMed ID: 6274534
[TBL] [Abstract][Full Text] [Related]
29. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
30. A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity.
Eder JP; Wheeler CA; Teicher BA; Schnipper LE
Cancer Res; 1991 Jan; 51(2):510-3. PubMed ID: 1985770
[TBL] [Abstract][Full Text] [Related]
31. Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Chauncey TR; Gooley TA; Lloid ME; Schubert MM; Lilleby K; Holmberg L; Bensinger WI
Am J Clin Oncol; 2000 Aug; 23(4):406-11. PubMed ID: 10955873
[TBL] [Abstract][Full Text] [Related]
32. I.v. melphalan in carcinoma of the lung: effect of cyclophosphamide priming on hematopoietic toxicity.
Spitzer G; Valdivieso M; Farha P; Murphy WK; Dhingra HM; Chiuten D; Umsawasdi T; Holoye P
Cancer Treat Rep; 1986 Apr; 70(4):449-53. PubMed ID: 3698037
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Fouladi M; Stempak D; Gammon J; Klein J; Grant R; Greenberg ML; Koren G; Baruchel S
Cancer; 2001 Aug; 92(4):914-23. PubMed ID: 11550166
[TBL] [Abstract][Full Text] [Related]
34. Phase I clinical investigation of homoharringtonine.
Legha SS; Keating M; Picket S; Ajani JA; Ewer M; Bodey GP
Cancer Treat Rep; 1984 Sep; 68(9):1085-91. PubMed ID: 6478448
[TBL] [Abstract][Full Text] [Related]
35. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
[TBL] [Abstract][Full Text] [Related]
36. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa.
Heideman RL; Cole DE; Balis F; Sato J; Reaman GH; Packer RJ; Singher LJ; Ettinger LJ; Gillespie A; Sam J
Cancer Res; 1989 Feb; 49(3):736-41. PubMed ID: 2491958
[TBL] [Abstract][Full Text] [Related]
37. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
Hendricks CB; Grochow LB; Rowinsky EK; Forastiere AA; McGuire WP; Ettinger DS; Sartorius S; Lubejko B; Donehower RC
Cancer Res; 1991 Nov; 51(21):5781-5. PubMed ID: 1933848
[TBL] [Abstract][Full Text] [Related]
38. IV melphalan in children.
Belasco JB; Mitchell CD; Rohrbaugh T; Rosenstock J
Cancer Treat Rep; 1987 Dec; 71(12):1277-8. PubMed ID: 3690538
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
Coleman CN; Friedman MK; Jacobs C; Halsey J; Ignoffo R; Leibel S; Hirst VK; Gribble M; Carter SK; Phillips TL
Cancer Res; 1983 Oct; 43(10):5022-5. PubMed ID: 6883348
[TBL] [Abstract][Full Text] [Related]
40. Pediatric phase I trial of carboplatin: a Childrens Cancer Study Group report.
Gaynon PS; Ettinger LJ; Moel D; Siegel SE; Baum ES; Krivit W; Hammond GD
Cancer Treat Rep; 1987 Nov; 71(11):1039-42. PubMed ID: 3315195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
